|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SFTA1P |
Gene summary for SFTA1P |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SFTA1P | Gene ID | 207107 |
| Gene name | surfactant associated 1, lncRNA | |
| Gene Alias | SFTPF | |
| Cytomap | 10p14 | |
| Gene Type | pseudo | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 207107 | SFTA1P | RNA-P10T2-P10T2-4 | Human | Lung | AAH | 6.64e-04 | 7.47e-01 | -0.138 |
| 207107 | SFTA1P | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 2.09e-17 | 7.26e-01 | -0.2116 |
| 207107 | SFTA1P | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 1.55e-07 | 8.08e-01 | -0.1941 |
| 207107 | SFTA1P | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 6.87e-06 | 6.29e-01 | -0.2107 |
| 207107 | SFTA1P | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 5.18e-08 | 6.34e-01 | -0.2119 |
| 207107 | SFTA1P | RNA-P6T1-P6T1-2 | Human | Lung | MIAC | 2.39e-03 | 5.49e-01 | -0.0186 |
| 207107 | SFTA1P | RNA-P6T1-P6T1-3 | Human | Lung | MIAC | 3.21e-02 | 6.27e-01 | -0.0296 |
| 207107 | SFTA1P | RNA-P6T1-P6T1-4 | Human | Lung | MIAC | 5.12e-05 | 5.19e-01 | -0.0263 |
| 207107 | SFTA1P | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 2.01e-11 | 3.91e-01 | -0.0166 |
| 207107 | SFTA1P | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 1.13e-06 | 2.38e-01 | -0.0132 |
| 207107 | SFTA1P | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 2.47e-15 | 3.35e-01 | -0.013 |
| 207107 | SFTA1P | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 1.31e-05 | 2.51e-01 | -0.0121 |
| 207107 | SFTA1P | C04 | Human | Oral cavity | OSCC | 4.85e-12 | 8.12e-01 | 0.2633 |
| 207107 | SFTA1P | C21 | Human | Oral cavity | OSCC | 7.00e-15 | 6.79e-01 | 0.2678 |
| 207107 | SFTA1P | C30 | Human | Oral cavity | OSCC | 2.82e-04 | 4.71e-01 | 0.3055 |
| 207107 | SFTA1P | C06 | Human | Oral cavity | OSCC | 1.43e-02 | 4.92e-01 | 0.2699 |
| 207107 | SFTA1P | SYSMH5 | Human | Oral cavity | OSCC | 8.75e-05 | 1.68e-01 | 0.0647 |
| 207107 | SFTA1P | ATC2 | Human | Thyroid | ATC | 1.85e-28 | 2.18e+00 | 0.34 |
| 207107 | SFTA1P | ATC3 | Human | Thyroid | ATC | 4.97e-10 | 5.41e-01 | 0.338 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |